Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Sepiapterin by PTC Therapeutics for Phenylketonuria (PKU): Likelihood of Approval
Sepiapterin is under clinical development by PTC Therapeutics and currently in Phase III for Phenylketonuria (PKU). According to GlobalData, Phase...
Data Insights
Risk adjusted net present value: What is the current valuation of PTC Therapeutics's Sepiapterin?
Sepiapterin is a small molecule commercialized by PTC Therapeutics, with a leading Phase III program in Phenylketonuria (PKU). According to...